TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

Idiopathic pulmonary fibrosis (IPF) is characterized by a progressive decline in lung function, worsening quality of life, and high mortality. However, the rate and pattern of progression of IPF ...

Maria L. Padilla, MD, Icahn School of Medicine at Mount Sinai, previews that experts will discuss critical management strategies for interstitial lung disease and idiopathic pulmonary fibrosis, ...

Under the terms of the agreement, Surrozen will provide antibody discovery services for a period of up to two years. TCGFB will own all TGF-β product related intellectual property. In exchange for ...

The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...

Research collaboration to leverage Surrozen's antibody research capabilities and expertise to discover a potential first in class <a target=_blank ...

Idiopathic pulmonary fibrosis (IPF) is a debilitating idiopathic lung disease that leads to early death. There are no effective medical therapies for IPF. Recent discoveries have identified a ...

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.

Swigris, DO, MS: Hello. I'm Dr Jeff Swigris. Welcome to season 2 of the Medscape InDiscussion podcast series on idiopathic pulmonary fibrosis. Today we are going to discuss the topic of genetics ...